RNA-binding proteins as drivers of AML and novel therapeutic targets

References

• Kim MY, Hur J, Jeong S. Emerging roles of RNA and RNA-binding protein network in cancer cells. BMB Rep. 2009;42(3):125–130.
   PubMed Web of Science ®Google Scholar
• Moore MJ. From birth to death: the complex lives of eukaryotic mRNAs. Science. 2005;309(5740):1514–1518.
   PubMed Web of Science ®Google Scholar
• Nguyen D, Lu Y, Chu KL, et al. HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells. Nat Commun. 2020;11(1):2026.
   PubMed Web of Science ®Google Scholar
• Dahlem C, Barghash A, Puchas P, et al. The insulin-like growth factor 2 mRNA binding protein IMP2/IGF2BP2 is overexpressed and correlates with poor survival in pancreatic cancer. Int J Mol Sci. 2019;20(13):3204.
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhang Z, Zhang S, et al. RNA binding protein RNPC1 inhibits breast cancer cell metastasis via activating STARD13-correlated ceRNA network. Mol Pharm. 2018;15(6):2123–2132.
   PubMedGoogle Scholar
• Mura M, Hopkins TG, Michael T, et al. LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene. 2015;34(39):5025–5036.
   PubMed Web of Science ®Google Scholar
• Kang MH, Jeong KJ, Kim WY, et al. Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer. Oncogene. 2017;36(12):1745–1752.
   PubMed Web of Science ®Google Scholar
• Kang MH, Jeong KJ, Kim WY, et al. Correction: Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer. Oncogene. 2019;38(22):4427–4428.
   PubMed Web of Science ®Google Scholar
• Wang ZL, Li B, Luo YX, et al. Comprehensive genomic characterization of RNA-binding proteins across human cancers. Cell Rep. 2018;22(1):286–298.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Ebert BL. The biology and clinical impact of genetic lesions in myeloid malignancies. Blood. 2013;122(23):3741–3748.
   PubMed Web of Science ®Google Scholar
• Wurth L. Versatility of RNA-binding proteins in cancer. Comp Funct Genomics. 2012;2012:178525.
   PubMedGoogle Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Dohner K, Paschka P, Dohner H. Acute myeloid leukemia. Internist. 2015;56(4):354–363.
   PubMed Web of Science ®Google Scholar
• Seiler M, Peng S, Agrawal AA, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018;23(1):282–296.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367–1376.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Isquith J, Zipeto MA, et al. Hyper-editing of cell-cycle regulatory and tumor suppressor RNA promotes malignant progenitor propagation. Cancer Cell. 2019;35(1):81–94.
   PubMed Web of Science ®Google Scholar
• Wang E, Lu SX, Pastore A, et al. Targeting an RNA-binding protein network in acute myeloid leukemia. Cancer Cell. 2019;35(3):369–384.
   PubMed Web of Science ®Google Scholar
• Beauchamp EM, Abedin SM, Radecki SG, et al. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Blood. 2019;133(11):1171–1185.
   PubMed Web of Science ®Google Scholar
• Liu F, Dai M, Xu Q, et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis. Oncogene. 2018;37(18):2394–2409.
   PubMed Web of Science ®Google Scholar
• Shkreta L, Toutant J, Durand M, et al. SRSF10 connects DNA damage to the alternative splicing of transcripts encoding apoptosis, cell-cycle control, and DNA repair factors. Cell Rep. 2016;17(8):1990–2003.
   PubMed Web of Science ®Google Scholar
• Hsiehchen D, Goralski M, Kim J, et al. Biomarkers for RBM39 degradation in acute myeloid leukemia. Leukemia. 2020;34(7):1924–1928.
   PubMed Web of Science ®Google Scholar
• Tong J, Xu X, Zhang Z, et al. Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica. 2020;105(6):1630–1640.
   PubMed Web of Science ®Google Scholar
• Pararajalingam P, Coyle KM, Arthur S, et al. Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020;136(5):572–584.
   PubMed Web of Science ®Google Scholar
• Zong L, Hattori N, Yasukawa Y, et al. LINC00162 confers sensitivity to 5-Aza-2'-deoxycytidine via modulation of an RNA splicing protein, HNRNPH1. Oncogene. 2019;38(26):5281–5293.
   PubMed Web of Science ®Google Scholar
• Drusbosky LM, Cogle CR. Identification of lenalidomide sensitivity and resistance mechanisms in non-Del(5q) myelodysplastic syndromes. Int J Mol Sci. 2020;21(9):3323.
   Web of Science ®Google Scholar
• Bamopoulos SA, Batcha A, Jurinovic V, et al. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia. 2020;34(10):2621–2634.
   PubMed Web of Science ®Google Scholar
• Xiao R, Chen JY, Liang Z, et al. Pervasive chromatin-RNA binding protein interactions enable RNA-based regulation of transcription. Cell. 2019;178(1):107–121.
   PubMed Web of Science ®Google Scholar
• Minuesa G, Albanese SK, Xie W, et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun. 2019;10(1):2691.
   PubMedGoogle Scholar
• Paris J, Morgan M, Campos J, et al. Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell. 2019;25(1):137–148.
   PubMed Web of Science ®Google Scholar
• Elcheva IA, Wood T, Chiarolanzio K, et al. RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1. Leukemia. 2020;34(5):1354–1363.
   PubMed Web of Science ®Google Scholar
• Palanichamy JK, Tran TM, Howard JM, et al. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest. 2016;126(4):1495–1511.
   PubMed Web of Science ®Google Scholar
• Sbarrato T, Horvilleur E, Poyry T, et al. A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment. Cell Death Dis. 2016;7(6):e2249.
   PubMedGoogle Scholar
• Ko CY, Wang WL, Li CF, et al. IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia. J Leukoc Biol. 2016;99(1):131–141.
   PubMed Web of Science ®Google Scholar
• Kudinov AE, Karanicolas J, Golemis EA, et al. Musashi RNA-Binding proteins as cancer drivers and novel therapeutic targets. Clin Cancer Res. 2017;23(9):2143–2153.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Peng L, Hu T, et al. La-related protein 4B maintains murine MLL-AF9 leukemia stem cell self-renewal by regulating cell cycle progression. Exp Hematol. 2015;43(4):309–318.
   PubMed Web of Science ®Google Scholar
• Cencic R, Robert F, Galicia-Vazquez G, et al. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J. 2013;3:e128.
   PubMed Web of Science ®Google Scholar
• Naarmann-de VI, Sackmann Y, Klein F, et al. Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region. Leuk Res. 2019;76:15–23.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu C, Xiong W, et al. Knockdown of p54nrb inhibits migration, invasion and TNF-α release of human acute monocytic leukemia THP1 cells. Oncol Rep. 2016;35(6):3742–3748.
   PubMed Web of Science ®Google Scholar
• Mazurek A, Park Y, Miething C, et al. Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5. Cell Rep. 2014;7(6):1887–1899.
   PubMed Web of Science ®Google Scholar
• He X, Li W, Liang X, et al. IGF2BP2 overexpression indicates poor survival in patients with acute myelocytic leukemia. Cell Physiol Biochem. 2018;51(4):1945–1956.
   PubMedGoogle Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–69.
   PubMed Web of Science ®Google Scholar
• Dvinge H, Kim E, Abdel-Wahab O, et al. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16(7):413–430.
   PubMed Web of Science ®Google Scholar
• Seiler M, Yoshimi A, Darman R, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med. 2018;24(4):497–504.
   PubMed Web of Science ®Google Scholar
• Obeng EA, Chappell RJ, Seiler M, et al. Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell. 2016;30(3):404–417.
   PubMed Web of Science ®Google Scholar
• Shirai CL, Ley JN, White BS, et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell. 2015;27(5):631–643.
   PubMed Web of Science ®Google Scholar
• Liang Y, Tebaldi T, Rejeski K, et al. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia. 2018;32(12):2659–2671.
   PubMed Web of Science ®Google Scholar
• Saygin C, Hirsch C, Przychodzen B, et al. Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J. 2018;8(1):4.
   PubMedGoogle Scholar
• Kon A, Yamazaki S, Nannya Y, et al. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood. 2018;131(6):621–635.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lieu YK, Ali AM, et al. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci Usa. 2015;112(34):E4726–E4734.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Armstrong RN, Steeples V, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood. 2018;132(12):1225–1240.
   PubMed Web of Science ®Google Scholar
• Han T, Goralski M, Gaskill N, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science. 2017;356(6336):eaal3755.
   PubMed Web of Science ®Google Scholar
• Mai S, Qu X, Li P, et al. Global regulation of alternative RNA splicing by the SR-rich protein RBM39. Biochim Biophys Acta. 2016;1859(8):1014–1024.
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, De Miranda J, Hornig M, et al. Toll-like receptor 3 regulates neural stem cell proliferation by modulating the Sonic Hedgehog pathway. PLoS One. 2011;6(10):e26766.
   PubMed Web of Science ®Google Scholar
• Zhou X, Li X, Cheng Y, et al. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun. 2014;5:4581.
   PubMed Web of Science ®Google Scholar
• Cloutier A, Shkreta L, Toutant J, et al. hnRNP A1/A2 and Sam68 collaborate with SRSF10 to control the alternative splicing response to oxaliplatin-mediated DNA damage. Sci Rep. 2018;8(1):2206.
   PubMedGoogle Scholar
• Naro C, Jolly A, Di Persio S, et al. An orchestrated intron retention program in meiosis controls timely usage of transcripts during germ cell differentiation. Dev Cell. 2017;41(1):82–93.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen JY, Huang YJ, et al. The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol Cell. 2018;69(3):412–425.
   PubMed Web of Science ®Google Scholar
• Barbouti A, Hoglund M, Johansson B, et al. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23). Cancer Res. 2003;63(6):1202–1206.
   PubMed Web of Science ®Google Scholar
• Saha S, Murmu KC, Biswas M, et al. Transcriptomic analysis identifies RNA binding proteins as putative regulators of myelopoiesis and leukemia. Front Oncol. 2019;9:692.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16(8):903–908.
   PubMed Web of Science ®Google Scholar
• Thol F, Winschel C, Sonntag AK, et al. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Ann Hematol. 2013;92(3):315–323.
   PubMed Web of Science ®Google Scholar
• Guzzi N, Ciesla M, Ngoc P, et al. Pseudouridylation of tRNA-derived fragments steers translational control in stem cells. Cell. 2018;173(5):1204–1216.
   PubMed Web of Science ®Google Scholar
• Barriga FM, Montagni E, Mana M, et al. Mex3a marks a slowly dividing subpopulation of Lgr5+ intestinal stem cells. Cell Stem Cell. 2017;20(6):801–816.
   PubMed Web of Science ®Google Scholar
• Vu LP, Prieto C, Amin EM, et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet. 2017;49(6):866–875.
   PubMed Web of Science ®Google Scholar
• Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 2017;552(7683):126–131.
   PubMed Web of Science ®Google Scholar
• Vu LP, Pickering BF, Cheng Y, et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23(11):1369–1376.
   PubMed Web of Science ®Google Scholar
• Weng H, Huang H, Wu H, et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell. 2018;22(2):191–205.
   PubMed Web of Science ®Google Scholar
• Wiseman DH, Bonney DK, Wynn RF. Hemophagocytosis by leukemic megakaryoblasts in acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1. J Pediatr Hematol Oncol. 2012;34(7):576–580.
   PubMed Web of Science ®Google Scholar
• Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 2017;31(1):127–141.
   PubMed Web of Science ®Google Scholar
• Park OH, Ha H, Lee Y, et al. Endoribonucleolytic cleavage of m6A-containing RNAs by RNase P/MRP complex. Mol Cell. 2019;74(3):494–507.
   PubMed Web of Science ®Google Scholar
• Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 2019;18(1):46.
   PubMed Web of Science ®Google Scholar
• Deforzh E, Vargas TR, Kropp J, et al. IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. Int J Oncol. 2016;49(6):2578–2588.
   PubMed Web of Science ®Google Scholar
• Li Z, Qian P, Shao W, et al. Author correction: suppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion. Cell Res. 2018;28(10):1042.
   PubMed Web of Science ®Google Scholar
• Wang H, Zuo H, Liu J, et al. Loss of YTHDF2-mediated m6A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration. Cell Res. 2018;28(10):1035–1038.
   PubMed Web of Science ®Google Scholar
• Qu X, Davison J, Du L, et al. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. Epigenetics. 2015;10(6):526–535.
   PubMed Web of Science ®Google Scholar
• Chang HM, Martinez NJ, Thornton JE, et al. Trim71 cooperates with microRNAs to repress Cdkn1a expression and promote embryonic stem cell proliferation. Nat Commun. 2012;3:923.
   PubMed Web of Science ®Google Scholar
• Wong DM, Li L, Jurado S, et al. The transcription factor ASCIZ and its target DYNLL1 are essential for the development and expansion of MYC-driven B cell lymphoma. Cell Rep. 2016;14(6):1488–1499.
   PubMed Web of Science ®Google Scholar
• King A, Li L, Wong DM, et al. Dynein light chain regulates adaptive and innate B cell development by distinctive genetic mechanisms. PLOS Genet. 2017;13(9):e1007010.
   PubMed Web of Science ®Google Scholar
• Zhou M, Tong X. Retraction note: downregulated poly-C binding protein-1 is a novel predictor associated with poor prognosis in acute myeloid leukemia. Diagn Pathol. 2018;13(1):69.
   PubMedGoogle Scholar
• Meinel DM, Strasser K. Co-transcriptional mRNP formation is coordinated within a molecular mRNP packaging station in S. cerevisiae. Bioessays. 2015;37(6):666–677.
   PubMed Web of Science ®Google Scholar
• Panas MD, Ivanov P, Anderson P. Mechanistic insights into mammalian stress granule dynamics. J Cell Biol. 2016;215(3):313–323.
   PubMed Web of Science ®Google Scholar
• Wende W, Friedhoff P, Strasser K. Mechanism and regulation of co-transcriptional mRNP assembly and nuclear mRNA export. Adv Exp Med Biol. 2019;1203:1–31.
   PubMed Web of Science ®Google Scholar
• Chang CT, Hautbergue GM, Walsh MJ, et al. Chtop is a component of the dynamic TREX mRNA export complex. Embo J. 2013;32(3):473–486.
   PubMed Web of Science ®Google Scholar
• Rha J, Jones SK, Fidler J, et al. The RNA-binding protein, ZC3H14, is required for proper poly(A) tail length control, expression of synaptic proteins, and brain function in mice. Hum Mol Genet. 2017;26(19):3663–3681.
   PubMed Web of Science ®Google Scholar
• Dufu K, Livingstone MJ, Seebacher J, et al. ATP is required for interactions between UAP56 and two conserved mRNA export proteins, Aly and CIP29, to assemble the TREX complex. Genes Dev. 2010;24(18):2043–2053.
   PubMed Web of Science ®Google Scholar
• Aibara S, Gordon JM, Riesterer AS, et al. Structural basis for the dimerization of Nab2 generated by RNA binding provides insight into its contribution to both poly(A) tail length determination and transcript compaction in Saccharomyces cerevisiae. Nucleic Acids Res. 2017;45(3):1529–1538.
   PubMed Web of Science ®Google Scholar
• Xing Z, Ma WK, Tran EJ. The DDX5/Dbp2 subfamily of DEAD-box RNA helicases. Wiley Interdiscip Rev Rna. 2019;10(2):e1519.
   PubMed Web of Science ®Google Scholar
• Martin-Exposito M, Gas ME, Mohamad N, et al. Mip6 binds directly to the Mex67 UBA domain to maintain low levels of Msn2/4 stress-dependent mRNAs. EMBO Rep. 2019;20(12):e47964.
   PubMed Web of Science ®Google Scholar
• Ma W K, Paudel B P, Xing Z, et al. Recruitment, duplex unwinding and protein-mediated inhibition of the dead-box RNA helicase Dbp2 at actively transcribed chromatin. J Mol Biol. 2016;428(6):1091–1106.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Liu Q, et al. Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene. 2010;29(4):539–549.
   PubMed Web of Science ®Google Scholar
• Wang R, Jiao Z, Li R, et al. p68 RNA helicase promotes glioma cell proliferation in vitro and in vivo via direct regulation of NF-κB transcription factor p50. Neuro Oncol. 2012;14(9):1116–1124.
   PubMed Web of Science ®Google Scholar
• Du C, Li DQ, Li N, et al. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway. Sci Rep. 2017;7:42876
   PubMed Web of Science ®Google Scholar
• Kokolo M, Bach-Elias M. Downregulation of p68 RNA helicase (DDX5) activates a survival pathway involving mTOR and MDM2 signals. Folia Biol. 2017;63(2):52–59.
   PubMed Web of Science ®Google Scholar
• Prosperi JR, Goss KH. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets. 2010;11(9):1074–1088.
   PubMed Web of Science ®Google Scholar
• Jung C, Mittler G, Oswald F, et al. RNA helicase Ddx5 and the noncoding RNA SRA act as coactivators in the Notch signaling pathway. Biochim Biophys Acta. 2013;1833(5):1180–1189.
   PubMed Web of Science ®Google Scholar
• Lin S, Tian L, Shen H, et al. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia. Oncogene. 2013;32(40):4845–4853.
   PubMed Web of Science ®Google Scholar
• Wu J, You YQ, Ma YX, et al. DDX5-targeting fully human monoclonal autoantibody inhibits proliferation and promotes differentiation of acute promyelocytic leukemia cells by increasing ROS production. Cell Death Dis. 2020;11(7):552.
   PubMed Web of Science ®Google Scholar
• Shen H. UAP56- a key player with surprisingly diverse roles in pre-mRNA splicing and nuclear export. BMB Rep. 2009;42(4):185–188.
   PubMed Web of Science ®Google Scholar
• Hautbergue GM, Hung ML, Walsh MJ, et al. UIF, a new mRNA export adaptor that works together with REF/ALY, requires FACT for recruitment to mRNA. Curr Biol. 2009;19(22):1918–1924.
   PubMed Web of Science ®Google Scholar
• Folco EG, Lee CS, Dufu K, et al. The proteins PDIP3 and ZC11A associate with the human TREX complex in an ATP-dependent manner and function in mRNA export. PLoS One. 2012;7(8):e43804.
   PubMed Web of Science ®Google Scholar
• Luo ML, Zhou Z, Magni K, et al. Pre-mRNA splicing and mRNA export linked by direct interactions between UAP56 and d Aly. Nature. 2001;413(6856):644–647.
   PubMed Web of Science ®Google Scholar
• Kang GJ, Park MK, Byun HJ, et al. SARNP, a participant in mRNA splicing and export, negatively regulates E-cadherin expression via interaction with pinin. J Cell Physiol. 2020;235(2):1543–1555.
   PubMed Web of Science ®Google Scholar
• Izumi H, McCloskey A, Shinmyozu K, et al. p54nrb/NonO and PSF promote U snRNA nuclear export by accelerating its export complex assembly. Nucleic Acids Res. 2014;42(6):3998–4007.
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Osawa T, Sasaki Y, et al. Overexpression of p54nrb/NONO induces differential EPHA6 splicing and contributes to castration-resistant prostate cancer growth. Oncotarget. 2018;9(12):10510–10524.
   PubMedGoogle Scholar
• Alfano L, Caporaso A, Altieri A, et al. NONO ubiquitination is mediated by FBW7 and GSK3 β via a degron lost upon chromosomal rearrangement in cancer. J Cell Physiol. 2018;233(5):4338–4344.
   PubMed Web of Science ®Google Scholar
• Takayama KI, Suzuki T, Fujimura T, et al. Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proc Natl Acad Sci USA. 2017;114(39):10461–10466.
   PubMed Web of Science ®Google Scholar
• Moreau-Gachelin F, Tavitian A, Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature. 1988;331(6153):277–280.
   PubMed Web of Science ®Google Scholar
• Beghini A, Ripamonti CB, Peterlongo P, et al. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. Hum Mol Genet. 2000;9(15):2297–2304.
   PubMed Web of Science ®Google Scholar
• Kraljacic BC, Arguello M, Amri A, et al. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 2011;25(7):1197–1200.
   PubMed Web of Science ®Google Scholar
• Altman JK, Szilard A, Konicek BW, et al. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood. 2013;121(18):3675–3681.
   PubMed Web of Science ®Google Scholar
• Assouline S, Culjkovic-Kraljacic B, Bergeron J, et al. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica. 2015;100(1):e7–e9.
   PubMed Web of Science ®Google Scholar
• Urtishak KA, Wang LS, Culjkovic-Kraljacic B, et al. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. 2019;38(13):2241–2262.
   PubMed Web of Science ®Google Scholar
• Wu H, Hu C, Wang A, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016;30(1):173–181.
   PubMed Web of Science ®Google Scholar
• Volpon L, Osborne MJ, Zahreddine H, et al. Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate. Biochem Biophys Res Commun. 2013;434(3):614–619.
   PubMed Web of Science ®Google Scholar
• Bussiere DE, Xie L, Srinivas H, et al. Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. Nat Chem Biol. 2020;16(1):15–23.
   PubMed Web of Science ®Google Scholar
• Faust TB, Yoon H, Nowak RP, et al. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15. Nat Chem Biol. 2020;16(1):7–14.
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian HM, Kadia TM, et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018;124(13):2758–2765.
   PubMed Web of Science ®Google Scholar
• Finci LI, Zhang X, Huang X, et al. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action. Genes Dev. 2018;32(3-4):309–320.
   PubMed Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Naing A, et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2014;32(3):436–444.
   PubMed Web of Science ®Google Scholar
• Fan L, Lagisetti C, Edwards CC, et al. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol. 2011;6(6):582–589.
   PubMed Web of Science ®Google Scholar
• Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597–601.
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005;105(8):3303–3311.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44(1):151–157.
   PubMed Web of Science ®Google Scholar
• Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009;114(15):3265–3275.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Maeda A, Chachad D, et al. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Sci. 2015;106(12):1705–1713.
   PubMed Web of Science ®Google Scholar
• Kushwaha AC, Mohanbhai SJ, Sardoiwala MN, et al. Epigenetic regulation of Bmi1 by ubiquitination and proteasomal degradation inhibit Bcl-2 in acute myeloid leukemia. ACS Appl Mater Interfaces. 2020;12(23):25633–25644.
   PubMed Web of Science ®Google Scholar
• Guo J, Russell EG, Darcy R, et al. Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy. Mol Pharm. 2017;14(3):940–952.
   PubMedGoogle Scholar
• D’Amico D, Mottis A, Potenza F, et al. The RNA-binding protein PUM2 impairs mitochondrial dynamics and mitophagy during aging. Mol Cell. 2019;73(4):775–787.
   PubMed Web of Science ®Google Scholar
• Yuan M, Webb E, Lemoine NR, et al. CRISPR-Cas9 as a powerful tool for efficient creation of oncolytic viruses. Viruses. 2016;8(3):72.
   PubMed Web of Science ®Google Scholar
• Schumann K, Lin S, Boyer E, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA. 2015;112(33):10437–10442.
   PubMed Web of Science ®Google Scholar
• Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539(7630):479.
   PubMed Web of Science ®Google Scholar
• Soundararajan S, Wang L, Sridharan V, et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol Pharmacol. 2009;76(5):984–991.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yoshimi A, Wang J, et al. Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization. Cancer Discov. 2020;10(6):806–821.
   Web of Science ®Google Scholar